Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
---|---|---|---|---|---|
Count | 0 | 0 | 0 | 0 | 0 |
% | 0 | 0 | 0 | 0 | 0 |
[Dilip Davda] Investors may consider investment for the long term. Based on financial parameters (including P/BV data) issue appears reasonably priced. Promoters have converted shares at Rs. 66 while the issue is priced lower. Employees too are offered shares at the same price of IPO. Read detail review...
Par Drugs IPO Reviews, analysis and views by popular members. Read Par Drugs & Chemicals Ltd. IPO reviews by retail investors to find recommended ipo to buy.
Review By | Apply | May Apply | Neutral | Avoid |
---|---|---|---|---|
Count | 0 | 0 | 0 | 0 |
% | 0.00 | 0.00 | 0.00 | 0.00 |
Member | Review |
---|---|
No recommendation found. Be the first to post the recommendation. |
Note: